Skip to main content
Category

News Archive

women-in-bio-logo

WIB-Capital Region Hosts Baltimore Mixer

By News Archive

women-in-bio-logo

Tuesday, June 19, 2018 – 5:30 p.m. – 7:30 p.m. EST

It’s been a wonderful spring for Women In Bio in Baltimore. Local organizers have put on amazing morning meet-ups featuring outstanding women scientists-entrepreneurs and business leaders. Let’s cap off this “season” with a Capital Region chapter-wide event. At this evening mixer, we’ll get to know each other more and meet new people in the bio scene in Baltimore and beyond.

Read More
pharma-drugs-pixa

Expanding horizons for risk management in pharma – McKinsey & Company

By News Archive

pharma-drugs-pixa

Risk management has become a top-of-mind issue for C-suites and boards around the world—nowhere more than in pharmaceutical companies. In a politically and economically turbulent environment, the risks pharma companies face, especially in clinical-trial design and execution, drug approval, product quality, and global commercial practices, are increasing in both frequency and magnitude.

Read More
carb-x-logo

REMINDER – CARB-X’s 2018 Funding Round 2 is now open for applications until June 8, 2018 at 5 PM EST

By News Archive

carb-x-logo

Apply now!

CARB-X 2018 Funding Round 2 is open for applications until June 8, 2018, 5 PM EST. Expressions of Interest are welcome on-line only.

The scope of Round 2 funding is broad and includes therapeutics, vaccines, microbiome, diagnostics and other life-saving products for certain drug-resistant and difficult-to-treat pathogens. 

Detailed information about the scope of Round 2 can be found here.

Information about how to apply for CARB-X funding can be found here. The on-line link to submit an Expression of Interest is now live, and will be live until June 8 at 5 PM EST.

Read More
ceres-nano-logo

Ceres Nanosciences reaches product development milestone for point-of-care Lyme disease test and closes on an additional $5.5M of Series A funding.

By News Archive

ceres-nano-logo

Ceres Nanosciences (Ceres) is announcing today that it has reached a key product development milestone for its Nanotrap® Lyme Antigen Test System. The Nanotrap® Lyme Antigen Test System will proceed into manufacturing and analytical performance testing this year and is on track for clinical study and FDA submission in 2019.

Read More

Search

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

BioHealth Innovation will use the information you provide on this form to be in touch with you and to provide updates and marketing.